Asset overview
Program snapshot
Target: Unknown
Cell type: NK_CELL
Indications: Pancreatic Cancer
Sponsor: Asclepius Technology Company Group (Suzhou) Co., Ltd.
Institution: Asclepius Technology Company Group (Suzhou) Co., Ltd.
Car Nk
BiCAR-NK cells (ROBO1 CAR-NK cells)
BiCAR-NK cells (ROBO1 CAR-NK cells) is flagged as a platform signal because it has an active early-phase oncology cell-therapy trial at Asclepius Technology Company Group (Suzhou) Co., Ltd., with a possible patent signal linked through modality_match. Manual review is still required.
Clinical evidence
Trial footprint
Phase: Phase1
Status: Unknown
Trial count: 1
Active trials: 0
First posted: May 8, 2019
Last updated: May 8, 2019
Signal summary
IP and BD posture
IP signal: Possible
BD label: Platform Signal
Confidence: Medium
Manual review required: Yes
Scores
Deterministic scoring
Clinical translation0
IP linkage3
Licensing clarity2
Strategic interest2
Source
Public trial record
Review the underlying ClinicalTrials.gov record and treat Treelip output as a prioritization layer, not a final diligence conclusion.
NCT IDs: NCT03941457